Paper Details
- Home
- Paper Details
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Author: BrandenburgTim, DralleHenning, FührerDagmar, MuchallaPhilipp, SchmidKurt Werner, TheurerSarah, TiedjeVera, WeberFrank
Original Abstract of the Article :
The tyrosine kinase inhibitors (TKI) vandetanib and cabozantinib are approved as targeted therapies in advanced medullary thyroid carcinoma (MTC) with symptoms or high tumour burden. Only recently, toxicity in long-time TKI usage was analysed. However, little is known about the impact of TKI discont...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511790/
データ提供：米国国立医学図書館（NLM）
Medullary Thyroid Carcinoma: A Desert Oasis of Hope with Targeted Therapies
Medullary thyroid carcinoma (MTC), like a stubborn desert shrub, can be difficult to treat. However, targeted therapies like vandetanib and cabozantinib have emerged as powerful weapons against this disease, providing much-needed relief for patients. This research, like a caravan exploring the diverse landscape of MTC treatment, investigates the impact of discontinuing these targeted therapies after long-term use. The study highlights the importance of monitoring patients closely for potential side effects and carefully weighing the benefits and risks of long-term treatment with these therapies. This research emphasizes the need for personalized approaches to MTC treatment, taking into account individual patient needs and potential side effects.
Navigating the Desert: A Personalized Approach to MTC Treatment
This study underscores the importance of individualized treatment strategies for MTC. While targeted therapies offer hope, the potential for toxicity and side effects necessitates careful monitoring and a personalized approach to ensure optimal outcomes for patients.
A Balancing Act: Managing MTC and Its Treatment
MTC treatment, like a delicate balancing act, requires careful consideration of the potential benefits and risks of targeted therapies. This research highlights the need for a personalized approach, balancing the potential for tumor control with the need to manage potential side effects, ensuring the best possible quality of life for patients.
Dr.Camel's Conclusion
This research takes us on a journey through the complex landscape of MTC treatment, emphasizing the importance of a personalized approach to manage this disease. Like a skilled camel caravan navigating a challenging desert, we must carefully balance the potential benefits and risks of targeted therapies to achieve optimal outcomes for patients.
Date :
- Date Completed 2022-02-11
- Date Revised 2022-04-14
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.